What is Proprio?
Proprio operates at the cutting edge of medical technology, integrating robotics, computer vision, machine learning, and immersive computing to augment surgical performance. The company's core value proposition lies in its ability to synthesize vast amounts of intraoperative data, providing surgeons with real-time, actionable insights that were previously inaccessible. By creating a digital twin of the surgical field, Proprio enhances the precision of complex procedures, effectively reducing variability and improving the overall quality of care. This technological synthesis positions the company as a critical infrastructure provider in the modern surgical suite, catering to the growing demand for data-driven, minimally invasive interventions.
How much funding has Proprio raised?
Proprio has raised a total of $66M across 2 funding rounds:
Series A
$23M
Series B
$43M
Series A (2020): $23M with participation from Alan Frazier, Cota Capital, and BOLD Capital Partners
Series B (2023): $43M, investors not publicly disclosed
Key Investors in Proprio
Cota Capital
Cota Capital is an investment firm that focuses on early-stage technology companies addressing innovative challenges in the enterprise sector, combining financial investment with deep operational expertise.
Alan Frazier
Alan Frazier is a prominent investor and the founder of East Seattle Partners and Frazier Healthcare Partners, known for his extensive experience in the healthcare investment landscape.
BOLD Capital Partners
BOLD Capital Partners is a venture capital firm that invests in high-growth companies, often focusing on breakthrough technologies that have the potential to disrupt traditional industries.
What's next for Proprio?
With the recent infusion of capital, Proprio is poised to transition from its current development and validation phase into a broader commercialization strategy. The company is expected to focus on expanding its clinical footprint, deepening its research and development efforts in machine learning, and scaling its manufacturing capabilities to meet enterprise-level demand. Strategic priorities will likely include securing additional regulatory clearances and fostering partnerships with major hospital systems to integrate its immersive computing platform into standard surgical workflows. As the company matures, its ability to maintain a competitive edge in the high-stakes medical robotics market will depend on its continued innovation in computer vision and the successful execution of its go-to-market strategy.
See full Proprio company page
